Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
Authors
Keywords
-
Journal
JAMA Network Open
Volume 4, Issue 2, Pages e2037120
Publisher
American Medical Association (AMA)
Online
2021-02-13
DOI
10.1001/jamanetworkopen.2020.37120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors
- (2020) Laura A. Petrillo et al. CANCER
- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy in lung cancer: effective for patients with poor performance status?
- (2020) Joao V Alessi et al. Lancet Respiratory Medicine
- Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
- (2020) Gary Middleton et al. Lancet Respiratory Medicine
- Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
- (2020) Alex Friedlaender et al. ACTA ONCOLOGICA
- Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
- (2020) Kartik Sehgal et al. Clinical Lung Cancer
- Performance Status in Cancer: Not Broken, But Time for an Upgrade?
- (2020) Jessica M. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
- (2020) Joao V Alessi et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
- (2019) Antonio Passaro et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153)
- (2019) David R. Spigel et al. Journal of Thoracic Oncology
- Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
- (2018) Aixa E. Soyano et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
- (2015) Holly G. Prigerson et al. JAMA Oncology
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Patients With Advanced Non–Small-Cell Lung Cancer and Marginal Performance Status: Walking the Tight Rope Towards Improved Survival
- (2013) Howard (Jack) West JOURNAL OF CLINICAL ONCOLOGY
- Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research
- (2008) Rogerio C. Lilenbaum et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now